🚀 VC round data is live in beta, check it out!
MiNK Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for MiNK Therapeutics and similar public comparables like Moberg Pharma, ProMIS Neurosciences, Cantourage Group, Cessatech and more.
MiNK Therapeutics Overview
About MiNK Therapeutics
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Founded
2017
HQ
Employees
23
Website
Sectors
Financials (LTM)
EV
$43M
MiNK Therapeutics Financials
MiNK Therapeutics reported last 12-month revenue of —.
Revenue (LTM)
MiNK Therapeutics P&L
In the most recent fiscal year, MiNK Therapeutics reported revenue of — and EBITDA of ($10M).
MiNK Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($10M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($11M) | XXX | XXX | XXX |
| Net Debt | — | — | $348K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MiNK Therapeutics Stock Performance
MiNK Therapeutics has current market cap of $51M, and enterprise value of $43M.
Market Cap Evolution
MiNK Therapeutics' stock price is $10.91.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43M | $51M | 0.0% | XXX | XXX | XXX | $-2.30 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMiNK Therapeutics Valuation Multiples
MiNK Therapeutics trades at (4.1x) EV/EBITDA.
MiNK Therapeutics Financial Valuation Multiples
As of March 18, 2026, MiNK Therapeutics has market cap of $51M and EV of $43M.
Equity research analysts estimate MiNK Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MiNK Therapeutics has a P/E ratio of (4.7x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $51M | XXX | $51M | XXX | XXX | XXX |
| EV (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.1x) | XXX | XXX | XXX |
| EV/EBIT | (2.9x) | XXX | (4.0x) | XXX | XXX | XXX |
| P/E | — | XXX | (4.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (4.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MiNK Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MiNK Therapeutics Margins & Growth Rates
MiNK Therapeutics' revenue in the last fiscal year grew by —.
MiNK Therapeutics' revenue per employee in the last FY averaged $0.0M.
MiNK Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | (54%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MiNK Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Moberg Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| ProMIS Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Cantourage Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Cessatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MiNK Therapeutics M&A Activity
MiNK Therapeutics acquired XXX companies to date.
Last acquisition by MiNK Therapeutics was on XXXXXXXX, XXXXX. MiNK Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MiNK Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMiNK Therapeutics Investment Activity
MiNK Therapeutics invested in XXX companies to date.
MiNK Therapeutics made its latest investment on XXXXXXXX, XXXXX. MiNK Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MiNK Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MiNK Therapeutics
| When was MiNK Therapeutics founded? | MiNK Therapeutics was founded in 2017. |
| Where is MiNK Therapeutics headquartered? | MiNK Therapeutics is headquartered in United States. |
| How many employees does MiNK Therapeutics have? | As of today, MiNK Therapeutics has over 23 employees. |
| Who is the CEO of MiNK Therapeutics? | MiNK Therapeutics' CEO is Jennifer S. Buell. |
| Is MiNK Therapeutics publicly listed? | Yes, MiNK Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of MiNK Therapeutics? | MiNK Therapeutics trades under INKT ticker. |
| When did MiNK Therapeutics go public? | MiNK Therapeutics went public in 2021. |
| Who are competitors of MiNK Therapeutics? | MiNK Therapeutics main competitors are Moberg Pharma, ProMIS Neurosciences, Cantourage Group, Cessatech. |
| What is the current market cap of MiNK Therapeutics? | MiNK Therapeutics' current market cap is $51M. |
| Is MiNK Therapeutics profitable? | No, MiNK Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.